News

We spoke to the first author of a new study that could challenge much of what we thought we knew about Alzheimer’s disease.
A recent study of patients who developed bipolar disorder or depression later in life revealed that half had high ...
Drugs that slow progression of Alzheimer’s don’t provide enough benefit to justify substantial cost for NHS, regulator has said ...
The team focused on Aβ42, a form of the amyloid beta with 42 amino acids that is commonly found in people with Alzheimer's disease. The researchers used three techniques in their work.
A new large-scale study has mapped the first molecular events that drive the formation of harmful amyloid protein aggregates found in Alzheimer's disease, pointing toward a new potential ...
Scientists have mapped how over 140,000 mutations affect the formation of amyloid beta fibrils, offering an unprecedented look at early events in Alzheimer’s disease.
Abstract The licensing of lecanemab and donanemab, disease-modifying immunotherapies for Alzheimer's disease (AD) targeting β-amyloid pathology, has been met with difference in opinion about efficacy, ...
UT Southwestern Scientists have identified the protein GADD45G as a master regulator of reactive gliosis, a damaging process in neurodegenerative diseases like Parkinson's.
The FDA approved a test that can help clinicians diagnose Alzheimer's disease early on using a simple blood draw. The test detects signs of amyloid plaque build-up in the brain.
Protein aggregation, such as amyloid beta (Aβ) and tau, is characteristic of AD, whereas alpha-synuclein aggregation occurs in PD.